Shaman Pharmaceuticals Inc. said it raised $10 million in around of venture capital financing, bringing to $23.1 million thetotal venture backing raised since its founding in 1989.

Shaman of San Carlos, Calif., is a drug-discovery companyworking on products derived from tropical plant sources. It hastwo drugs in clinical trials: Provir, an oral agent for treatingrespiratory viruses, and a topical treatment for herpes 1 and 2.An anti-fungal agent is in late preclinical development,according to the company.

New investors in the recent round included Invesco Trust Co.,H&Q Life Science Healthcare Investors, The Travelers Cos.,Fostin Capital and Prim Ventures. Twelve other investorsparticipated, including Shaman's early backers, TechnologyFunding Inc., Delphi BioVentures, Elf Technology and CalvertSocial Venture Fund.

S.G Warburg was the underwriter for the offering.

(c) 1997 American Health Consultants. All rights reserved.